Related Experiment Video
Updated: Sep 29, 2026
The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
[Mesoglycan in acute focal cerebral ischemia]
Abstract:
An open, randomized, controlled study including 57 patients with acute cerebral infarct was performed. All the patients, followed and controlled by the same examiner, received, in the first ten days, 24 mg/die i.v. of dexamethasone. 28 patients were also treated with mesoglycan (150 mg/die i.m. for five days and 144 mg/die per os for a further twenty-five days). The differences between the basal and final scores in the mesoglycan group and in the controls were not statistically significant as analysed by the Mann-Whitney U test. The mesoglycan influenced only slightly the laboratory values (PT, PTT, alkaline phosphatase, GOT, GPT, cholesterol and triglycerides, fibrinogen, blood glucose, azotemia and creatinine) performed before the beginning of the treatment, as their changes after thirty days of therapy were in the normal range. The mesoglycan was very well tolerated and no side-effects were observed during the treatment.
Insights
This study investigated mesoglycan
Area of Science:
- Neurology
- Pharmacology
Background:
- Acute cerebral infarct, or stroke, is a leading cause of disability.
- Dexamethasone is a corticosteroid often used in acute stroke management.
- Mesoglycan is a glycosaminoglycan with potential antithrombotic and neuroprotective properties.
Purpose of the Study:
- To evaluate the efficacy and safety of mesoglycan as an adjunct therapy in patients with acute cerebral infarct.
- To assess the impact of mesoglycan on neurological outcomes and laboratory parameters.
Main Methods:
- An open-label, randomized, controlled study was conducted with 57 patients diagnosed with acute cerebral infarct.
- All patients received intravenous dexamethasone for the initial ten days.
- Twenty-eight patients additionally received mesoglycan (intramuscularly for five days, then orally for twenty-five days).
Main Results:
- No statistically significant differences were observed in neurological scores between the mesoglycan group and the control group.
- Mesoglycan showed minimal influence on tested laboratory values, with changes remaining within normal ranges after thirty days.
- Mesoglycan was well-tolerated, and no adverse side effects were reported during the treatment period.
Conclusions:
- Mesoglycan, as an adjunct to dexamethasone, did not demonstrate a significant improvement in neurological outcomes for acute cerebral infarct patients.
- The study suggests that mesoglycan is safe and well-tolerated in this patient population.
- Further research may be needed to explore potential benefits in different stroke phases or patient subgroups.
Related Concept Videos
01:15Ischemic Stroke l: Introduction
01:15Ischemic Stroke ll: Pathophysiology
01:26Transient Ischemic Attack l: Introduction